DiaMedica Therapeutics (DMAC) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Surrozen (SRZN) has outperformed DiaMedica Therapeutics (DMAC) over the past year, gaining 72.6% versus a gain of 15.0%. Over five years, DMAC leads with a +88.3% price change compared with -76.7% for SRZN. DiaMedica Therapeutics is the larger company by market cap ($408.2 million vs $275.5 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMAC | SRZN |
|---|---|---|
| Share price | $7.57 | $23.44 |
| Market cap | $408.22M | $275.50M |
| 1-day change | -5.85% | -6.50% |
| YTD return | -4.90% | +3.72% |
| 1-year return | +15.05% | +72.61% |
| 5-year return | +88.31% | -76.75% |
| EPS (TTM) | $-0.72 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.48M |
| Revenue growth (YoY) | — | -67.37% |
| Net income (latest FY) | $-32.77M | $-242.03M |
| Operating margin | — | -1210.58% |
| Net margin | — | -6960.77% |
| 52-week high | $10.42 | $37.83 |
| 52-week low | $5.25 | $11.39 |
| Distance from 52-week high | -27.35% | -38.04% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +104.76% | +106.48% |
| Average volume | 182.81K | 534.47K |
| Shares outstanding | 53.93M | 11.75M |
| Employees | 35 | 44 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed DMAC by 57.6 percentage points over the past year.
About DiaMedica Therapeutics
DMAC stock →DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Healthcare · Biotechnology · 35 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Healthcare · Biotechnology · 44 employees
DMAC vs SRZN FAQ
Which is bigger, DiaMedica Therapeutics or Surrozen?
DiaMedica Therapeutics (DMAC) is larger, with a market capitalization of $408.22M compared with $275.50M for Surrozen (SRZN).
Which stock has performed better over the past year, DMAC or SRZN?
SRZN returned +72.61% over the past 12 months, compared with +15.05% for DMAC (price return, excluding dividends). Past performance does not predict future results.
Are DiaMedica Therapeutics and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.